Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2017
This article has no abstract
Epistemonikos ID: b190c8dce33b466ba22582844a930dd04be05242
First added on: Apr 16, 2025